Edition:
United States

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

16.82USD
3:33pm EDT
Change (% chg)

$0.04 (+0.24%)
Prev Close
$16.78
Open
$16.67
Day's High
$17.04
Day's Low
$16.59
Volume
283,107
Avg. Vol
368,075
52-wk High
$17.55
52-wk Low
$8.18

Chart for

About

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex... (more)

Overall

Beta: 2.22
Market Cap(Mil.): $2,381.34
Shares Outstanding(Mil.): 141.92
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 60.89 15.95
EPS (TTM): -- -- --
ROI: -- 0.19 15.19
ROE: -- 2.32 13.87

Halozyme to license drug delivery tech to Roche, Bristol-Myers

U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations.

Sep 14 2017

BRIEF-Halozyme licenses new Enhanze target for $30 mln upfront payment

* Halozyme licenses new enhanze target for $30 million upfront payment, future milestones and royalties

Sep 14 2017

Halozyme to license drug delivery tech to Roche, Bristol-Myers

Sept 14 U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations.

Sep 14 2017

BRIEF-Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology

* Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology

Sep 14 2017

BRIEF-Halozyme reports Q2 loss per share $0.23

* Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S

Aug 08 2017

BRIEF-Halozyme announces initiation of clinical trial collaboration

* Initiation of clinical trial collaboration evaluating Halozyme's pegph20 in combination with anti-PDL1 immunotherapy

Jul 13 2017

BRIEF-Halozyme Therapeutics, unit entered into first amendment to amended, restated lease with BMR-11388 Sorrento Valley Road

* Halozyme Therapeutics Inc - co, unit entered into a first amendment to amended and restated lease with bmr-11388 sorrento valley road lp

Jul 05 2017

BRIEF-Halozyme phase 2 data in advanced pancreas cancer presented

* Halozyme phase 2 data in advanced pancreas cancer presented at european society for medical oncology symposium

Jun 28 2017

BRIEF-Halozyme Therapeutics prices public offering of common stock

* Halozyme Therapeutics prices public offering of common stock

May 18 2017

BRIEF-Halozyme Therapeutics announces public offering of common stock

* Halozyme Therapeutics announces public offering of common stock

May 18 2017

Competitors

  Price Chg
Novo Nordisk A/S (NOVOb.CO) kr.308.60 +2.80
Sanofi SA (SASY.PA) €84.64 +0.52
Eli Lilly and Co (LLY.N) $84.52 +0.61
Albireo Pharma Inc (ALBO.OQ) $22.11 -0.13
MannKind Corporation (MNKD.OQ) $1.92 -0.05

Earnings vs. Estimates